ESTROGEL (estradiol) by Ascend Therapeutics is estrogen receptor agonists [moa]. Approved for menopause, contraception. First approved in 2004.
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
ESTROGEL is a transdermal estradiol gel approved in 2004 for hormone replacement therapy in menopause and related conditions. It works as an estrogen receptor agonist to replace declining estrogen levels and treat vasomotor symptoms, vaginal atrophy, and other menopausal sequelae. The drug has a broad off-label indication profile spanning contraception, metabolic disease, autoimmune conditions, and cancer treatment.
Mature, low-revenue product with approaching loss of exclusivity signals limited team growth and defensive positioning rather than expansion opportunity.
Estrogen Receptor Agonists
Estrogen
Evaluate the Effect of Vimseltinib on Pharmacokinetics of Combined Oral Contraceptive (Ethinyl Estradiol/Levonorgestrel)
A Trial to Examine the Interaction of Repinatrabit With Ethinyl Estradiol/Norethindrone, Metformin,Carbamazepine, Rosuvastatin, and Methotrexate When Administered Together
A Phase 1 Study to Assess the Effect of ABBV-722 on Ethinyl Estradiol and Levonorgestrel Drug Levels in Healthy Adult Female Participants
Estradiol-mediated Inflammation and Central Sensitization in the Pathophysiology of Endometriosis-associated Pelvic Pain
Drug-drug Interaction Study of Bemnifosbuvir/Ruzasvir (BEM/RZR) and Ethinyl Estradiol/Levonorgestrel (EE/LNG)
Worked on ESTROGEL at Ascend Therapeutics? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moESTROGEL offers limited career growth opportunity given its low commercial profile ($1M Part D spending, 4,587 claims), mature lifecycle status, and approaching loss of exclusivity. Roles on this product are primarily defensive—managing formulary access, optimizing pricing, and supporting sales to a stable but shrinking patient base.